In Brief This Week: CombiMatrix; SQI Diagnostics, Gamma-Dynacare; NuGen; Evotec; WaferGen Biosystems | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CombiMatrix said this week that its subsidiary, CombiMatrix Molecular Diagnostics, has received approval from Medicare to begin billing for its array-based diagnostic tests. The subsidiary offers array-based cancer tests through its Irvine, Calif.-based CLIA-certified lab.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.